BSBabur Salim

Babur Salim

*This is an algorithmically generated author record based on publicly available information.

Babur Salim has a total of 195 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    2024 Update of the Asia‐Pacific League of Associations for Rheumatology ( APLAR ) Recommendations for Rheumatoid Arthritis Management

    by Kunihiro Yamaoka, Zhanguo Li, Khin Thin Zar Myo Aung, Paul Bird, Manisha Bhochhibhoya, Minhaj Rahim Choudhury, Debashish Danda, Tsolmon Darisuren, Rudy Hidayat, Nguyen Van Hung, et al.

    Aim: To update the Asia‐Pacific League of Associations for Rheumatology (APLAR) treatment recommendations for rheumatoid arthritis (RA) by incorporating new evidence and reassessing the validity of previous guidance: Methods: A literature search for relevant publications from January 2018 to August 2023 was conducted, supplemented by earlier studies where relevant. Recommendations were formulated based on this evidence and refined through a modified‐Delphi process during a series of online meetings. The quality of evidence and strength of recommendations were assessed using the Grading of Recommendations, Assessment, Development and Evaluations (GRADE) approach. Results: This update comprises 14 statements that achieved consensus during the meetings. Topics covered include measurement of disease activity and treatment response, the use of conventional synthetic disease‐modifying antirheumatic drugs (csDMARDs), the use of targeted therapies, vaccination and screening for infections and the use of DMARDs during pregnancy. The recommendations address the selection of disease activity scores, initiation and intensification of therapy using csDMARDs and targeted therapies, and management of RA in patients at risk of reactivation of infectious diseases. These recommendations are discussed in the context of the clinical landscape encountered in the Asia‐Pacific region. Conclusion: These updated recommendations complement previous APLAR guidelines and aim to support best practice management of RA across the Asia‐Pacific region. They provide a practical framework for national rheumatology associations to develop local guidelines adapted to their specific needs and clinical practice.


  • Discordance in Patient and Physician's Perception of Disease Activity Among Idiopathic Inflammatory Myopathy Patients: Insights From the COVAD Study

    by Rudra P. Goswami, Parikshit Sen, Zoha Zahid Fazal, Jasmine Parihar, Yogesh Preet Singh, R. Naveen, James B. Lilleker, Mrudula Joshi, Vishwesh Agarwal, Arvind Nune, et al.


  • Open Access

    Anti-Ro Positivity in Systemic Lupus Erythematosus: Association with Clinical Phenotypes and Serological Profile

    by Anum Khan, Shahida Perveen, Haris Gul, Babur Salim, Saba Samreen, Umme Laila Hashmi

    Objective: To determine the association of anti-Ro antibody with the clinical features and serology in systemic lupus erythematosus (SLE) patients. Methods: This retrospective observational study enrolled 158 SLE patients at the Rheumatology Department, Fauji Foundation Hospital, from May 1 to October 31, 2023. Demographic and clinical data were collected. Patients were stratified by anti-Ro (positive vs. negative), concomitant anti-La (anti-Ro[ ]/anti-La[ ], anti-Ro[ ]/anti-La[ ], anti-Ro[ ]/anti-La[ ], and anti-Ro[ ]/anti-La[ ]), and anti-nuclear antibody (ANA) status (positive vs. negative). Mann-Whitney U and Chi-square tests were employed for comparisons, with statistical significance set at p<0.05. Results: The study population consisted mainly of females (98.7%), with a median age of 30 years. Anti-Ro[ ] patients (46.8%) exhibited higher discoid rash (16.2% vs. 6%, p [ ] 0.04), sicca symptoms (52.7% vs. 31%, p [ ] 0.005), and anemia (71.6% vs. 56%, p [ ] 0.04). No significant differences were observed in nephritis (29.7% vs. 34.5%, p [ ] 0.52) or neurological disease (9.5% vs. 11.9%, p [ ] 0.69) between the two groups. The anti-Ro[ ]/anti-La[ ] group had higher myositis (20.6%), sicca symptoms (55.9%), and fever (70.6%) compared to other groups. The ANA[ ]/anti-Ro[ ] group (48.6%) had significant association with sicca symptoms (50.7%) and fever (64.2%). Conclusion: Anti-Ro[ ] SLE in South Asians is associated with sicca symptoms, anemia, fever, and myositis—findings critical for tailored management. Co-positivity with anti-La amplifies risks, warranting vigilant monitoring.

  • Open Access

    Overcoming rheumatoid arthritis challenges: Ensuring timely referral to rheumatologists in resource-scarce countries

    by Anum Khan, Babur Salim, Shahida Perveen, Saba Samreen, Haris Gul, Amjad Nasim

    Article Overcoming rheumatoid arthritis challenges: Ensuring timely referral to rheumatologists in resource-scarce countries was published on December 1, 2023 in the journal Rheumatology and Immunology Research (volume 4, issue 4).


  • Open Access

    Abstract 13 — Comparison of Clinical and Serological Features in Juvenile and Adult-Onset Systemic Lupus Erythematosus

    by Babur Salim, Anum Khan, Haris Gul, Saba Samreen, Shahida Perveen

    Background Systemic lupus erythematosus (SLE) has varying clinical and serological features in juvenile and adult-onset disease groups, depending on the ethnicity. Objectives: To compare the disease characteristics of patients with adult-onset (ASLE) and juvenile-onset systemic lupus erythematosus (JSLE). Methods It is a cross-sectional study, carried out at Rheumatology department Fauji Foundation Hospital. 184 SLE patients were included. They were divided into adult (n=152) and juvenile (n=32) group. The clinical and serological features at the time of disease onset were compared between the two groups. Statistical analysis was done using chi square and t-test. Results The mean age was 36.22 ± 11.48 in adults and 19.94 ± 7.17 in the juvenile group (t = 7.71, p<0.001). The duration of disease was 46.05 ± 45.74 months(adult) and 62.43 ± 84.00 months (juvenile). There was no significant difference in disease activity, SLE disease activity index (SLEDAI) was 13 in adult lupus patients and 14.5 in the juvenile, t-value=1.1 and p-value=0.39. Sicca symptoms were significant in the ASLE (p=0.004). Neuropsychiatric manifestations (p=0.03), thrombocytopenia (p=0.048) and low complement levels (0.02) were significantly higher in JSLE. Serological profiles did not differ significantly in the two groups. Conclusion The features of SLE differ in adult and juvenile patients. Neurological involvement and thrombocytopenia were more prevalent in JSLE, whereas sicca symptoms were more frequently found in ASLE.

  • Flares of autoimmune rheumatic disease following COVID‐19 infection: Observations from the COVAD study

    by Nimrat Kaur Sandhu, Naveen Ravichandraan, Arvind Nune, Jessica Day, Parikshit Sen, Elena Nikiphorou, Ai Lyn Tan, Mrudula Joshi, Sreoshy Saha, Samuel Katsuyuki Shinjo, et al.


  • Open Access

    Long-term safety of COVID vaccination in individuals with idiopathic inflammatory myopathies: results from the COVAD study

    by Bohdana Doskaliuk, Naveen Ravichandran, Parikshit Sen, Jessica Day, Mrudula Joshi, Arvind Nune, Elena Nikiphorou, Sreoshy Saha, Ai Lyn Tan, Samuel Katsuyuki Shinjo, et al.

    Limited evidence on long-term COVID-19 vaccine safety in patients with idiopathic inflammatory myopathies (IIMs) continues to contribute to vaccine hesitancy. We studied delayed-onset vaccine adverse events (AEs) in patients with IIMs, other systemic autoimmune and inflammatory disorders (SAIDs), and healthy controls (HCs), using data from the second COVID-19 Vaccination in Autoimmune Diseases (COVAD) study. A validated self-reporting e-survey was circulated by the COVAD study group (157 collaborators, 106 countries) from Feb–June 2022. We collected data on demographics, comorbidities, IIM/SAID details, COVID-19 history, and vaccination details. Delayed-onset (> 7 day) AEs were analyzed using regression models. A total of 15165 respondents undertook the survey, of whom 8759 responses from vaccinated individuals [median age 46 (35–58) years, 74.4% females, 45.4% Caucasians] were analyzed. Of these, 1390 (15.9%) had IIMs, 50.6% other SAIDs, and 33.5% HCs. Among IIMs, 16.3% and 10.2% patients reported minor and major AEs, respectively, and 0.72% (n = 10) required hospitalization. Notably patients with IIMs experienced fewer minor AEs than other SAIDs, though rashes were expectedly more than HCs [OR 4.0; 95% CI 2.2–7.0, p < 0.001]. IIM patients with active disease, overlap myositis, autoimmune comorbidities, and ChadOx1 nCOV-19 (Oxford/AstraZeneca) recipients reported AEs more often, while those with inclusion body myositis, and BNT162b2 (Pfizer) recipients reported fewer AEs. Vaccination is reassuringly safe in individuals with IIMs, with AEs, hospitalizations comparable to SAIDs, and largely limited to those with autoimmune multimorbidity and active disease. These observations may inform guidelines to identify high-risk patients warranting close monitoring in the post-vaccination period.


  • Open Access

    High fatigue scores in patients with idiopathic inflammatory myopathies: a multigroup comparative study from the COVAD e-survey

    by Silvia Grignaschi, Minchul Kim, Giovanni Zanframundo, Naveen Ravichandran, James B. Lilleker, Parikshit Sen, Mrudula Joshi, Vishwesh Agarwal, Sinan Kardes, Jessica Day, et al.

    Idiopathic inflammatory myopathies (IIMs) confer a significant risk of disability and poor quality of life, though fatigue, an important contributing factor, remains under-reported in these individuals. We aimed to compare and analyze differences in visual analog scale (VAS) scores (0–10 cm) for fatigue (VAS-F) in patients with IIMs, non-IIM systemic autoimmune diseases (SAIDs), and healthy controls (HCs). We performed a cross-sectional analysis of the data from the COVID-19 Vaccination in Autoimmune Diseases (COVAD) international patient self-reported e-survey. The COVAD survey was circulated from December 2020 to August 2021, and details including demographics, COVID-19 history, vaccination details, SAID details, global health, and functional status were collected from adult patients having received at least one COVID-19 vaccine dose. Fatigue experienced 1 week prior to survey completion was assessed using a single-item 10 cm VAS. Determinants of fatigue were analyzed in regression models. Six thousand nine hundred and eighty-eight respondents (mean age 43.8 years, 72% female; 55% White) were included in the analysis. The overall VAS-F score was 3 (IQR 1–6). Patients with IIMs had similar fatigue scores (5, IQR 3–7) to non-IIM SAIDs [5 (IQR 2–7)], but higher compared to HCs (2, IQR 1–5; P < 0.001), regardless of disease activity. In adjusted analysis, higher VAS-F scores were seen in females (reference female; coefficient −0.17; 95%CI −0.21 to −13; P < 0.001) and Caucasians (reference Caucasians; coefficient −0.22; 95%CI −0.30 to −0.14; P < 0.001 for Asians and coefficient −0.08; 95%CI −0.13 to 0.30; P = 0.003 for Hispanics) in our cohort. Our study found that patients with IIMs exhibit considerable fatigue, similar to other SAIDs and higher than healthy individuals. Women and Caucasians experience greater fatigue scores, allowing identification of stratified groups for optimized multidisciplinary care and improve outcomes such as quality of life.


  • Open Access

    Systemic sclerosis and COVID-19 vaccine safety: short-term insights from the global COVID-19 vaccination in autoimmune disease (COVAD) survey

    by R. Naveen, Darpan R. Thakare, Masataka Kuwana, John D. Pauling, Jessica Day, Mrudula Joshi, Ioannis Parodis, Parikshit Sen, Kshitij Jagtap, Elena Nikiphorou, et al.

    The safety profile of COVID-19 vaccines is understudied in patients with systemic sclerosis (SSc). We compared short-term adverse events (AEs) 7 days following vaccination in patients with SSc vs other rheumatic (AIRDs), non-rheumatic autoimmune diseases (nrAIDs), and healthy controls (HCs). The COVID-19 Vaccination in autoimmune diseases (COVAD) self-reporting e-survey was circulated by a group of > 110 collaborators in 94 countries from March to December 2021. AEs were analyzed between different groups using regression models. Of 10,679 complete respondents [73.8% females, mean age 43 years, 53% Caucasians], 478 had SSc. 83% had completed two vaccine doses, Pfizer-BioNTech (BNT162b2) (51%) was the most common. Minor and major AEs were reported by 81.2% and 3.3% SSc patients, respectively, and did not differ significantly with disease activity or different vaccine types, though with minor symptom differences. Frequencies of AEs were not affected by background immunosuppression, though SSc patients receiving hydroxychloroquine experienced fatigue less commonly (OR 0.4; 95% CI 0.2–0.8). Frequency of AEs and hospitalisations were similar to other AIRDs, nrAIDs, and HC except a higher risk of chills (OR 1.3; 95% CI 1.0–1.7) and fatigue (OR 1.3; 95% CI 1.0–1.6) compared to other AIRDs. COVID-19 vaccines were largely safe and well tolerated in SSc patients in the short term. Background immunosuppression and disease activity did not influence the vaccination-related short-term AEs.


  • Higher risk of short term COVID-19 vaccine adverse events in myositis patients with autoimmune comorbidities: results from the COVAD study

    by Mrinalini Dey, R Naveen, Elena Nikiphorou, Parikshit Sen, Sreoshy Saha, James B Lilleker, Vishwesh Agarwal, Sinan Kardes, Jessica Day, Marcin Milchert, et al.